Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Regenerative Medicine Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NME7 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NME7 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native post-translational modifications. |
View NME7 Products |
| Gene Delivery | NME7 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and functional assays. |
View NME7 Products |
| Benchmark Ab | Anti-NME7 Antibody Recombinant positive control for Western Blot, ELISA, and Flow Cytometry. |
View NME7 Products |
| Validator | NME7 siRNA Set For target knockdown verification and specificity validation. |
View NME7 Products |
| Related Target A | NME1 Subfamily homolog; critical for off-target selectivity and counter-screening panels. |
View NME1 Products |
| Related Target B | NME2 Subfamily homolog; essential for assessing broad-spectrum NDPK inhibition vs. NME7-specific targeting. |
View NME2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against highly homologous NME family members (NME1/2) | Full panel of human NME family recombinant proteins available with >95% purity and verified molecular weight. |
| Conformation-dependent screening in cell-based functional assays | Lentivirus-based full-length NME7 expression systems designed to preserve native intracellular localization and macromolecular complexes. |
| Lack of Controls | High-affinity recombinant benchmark antibodies included for assay standardization. |
| False Positives | Sequence-specific siRNA pool included for target validation and knockdown control. |
Live NME7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NME7 therapeutics is intensifying, with major players shifting focus from traditional academic target validation to small molecule inhibitors and RNA-targeted therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting NME7's unique role in centrosome duplication, ciliary function, and cancer stem cell pluripotency. Given its high expression in metastatic solid tumors (including breast and oral cancers), developing highly selective inhibitors that do not cross-react with ubiquitously expressed family members like NME1 and NME2 remains the primary hurdle for drug developers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Metastatic Breast Cancer, Solid Tumors | Selectivity Assay (Need High-Purity NME1, NME2, and NME7 Proteins for kinase profiling) |
| RNAi / siRNA | Preclinical Stage Biopharma | Ciliopathies, Stem Cell Reprogramming | Knockdown Validation (Need Sequence-Verified siRNA and Lentivirus for stable expression) |
| Monoclonal Antibodies | Early-stage Discovery Groups | Oncology (Extracellular/Secreted NME7) | Epitope Mapping (Need HEK293-expressed recombinant NME7 with native glycosylation) |